Saturday, 5 September 2026European Markets

ASETEK Stock Over 30% Up In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of ASETEK (Oslo Børs Benchmark Index_GI: ASTK.OL) jumped by a staggering 30.77% in 21 sessions from kr3.9 to kr5.10 at 02:26 EST on Monday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is jumping 2.02% to kr1,226.27, after two sequential sessions in a row of gains.

About ASETEK

Asetek A/S, together with its subsidiaries, engages in the designing, developing, and marketing of liquid cooling solutions in Asia, Europe, and the Americas. The company operates through Liquid cooling, Data center and SimSports segments. Its products are used in personal computers, servers, and data centers to provide improved performance, acoustics, and energy efficiency. It serves original equipment manufacturers, resellers, and channel partners. The company was founded in 1997 and is headquartered in Aalborg, Denmark.

Earnings Per Share

As for profitability, ASETEK has a trailing twelve months EPS of kr-0.97.

Volatility

ASETEK's last week, last month's, and last quarter's current intraday variation average was 0.01%, 2.11%, and 11.11%.

ASETEK's highest amplitude of average volatility was 2.88% (last week), 7.26% (last month), and 11.11% (last quarter).

More news about ASETEK (ASTK.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com